Drug prices and cost of healthcare are two major concerns globally. This entails to examine the structure and performance of domestic pharmaceutical industry and Indian market’s pricing policy of drugs. This article contributes to the debate around regulation of drug prices in India from the perspectives of the healthcare of the poor and affordability.
Advanced Medical Technology Association & IQVIA. (2018). Medical devices in India: An agenda to effective health care delivery. https://www.advamed.org/sites/default/files/resource/medical_devices_in_india_-_an_agenda_to_effective_healthcare_delivery.pdf
2.
AliF.RajagopalS.RamanV. S.JohnR. (2018). Pharmaceutical patent grants in India: How our safeguards against evergreening have failed, and why the system must be reformed. Azim Premji University. https://accessibsa.org/media/2018/04/Pharmaceutical-Patent-Grants-in-India.pdf
3.
BhattacharjeaA.SindhwaniF. (2014). Competition issues in the Indian pharmaceuticals sector. Centre for Development Economics, Delhi School of Economics.
4.
Central Drug Standards Control Organisation. (2015). Report of expert committee on fixed dose combinations (FDCs) licensed by SLAs for manufacture without approval of DCG (I), applications of which received by CDSCO. http://www.cdsco.nic.in/writereaddata/fdcexpert%2019.1.2016.pdf
5.
Centre for Trade and Development. (2010). Competition law and Indian pharmaceutical industry. Centre for Trade and Development.
6.
DasK. (2003). The domestic politics of TRIPs: Pharmaceutical interests, public health, and NGO influence in India[Paper presentation]. Linking the WTO to the Poverty-Reduction Agenda. Gujarat Institute of Development Research.
7.
DiMasiJ. A.GrabowskiH. G.HansenR. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47(May), 20–33.
8.
DiMasiJ. A.HansenR. W.GrabowskiH. G.LasagnaL. (1991). Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10(2), 107–142.
9.
Drug prices: Case for enquiry. (1965). Economic & Political Weekly, 17(3), 79.
10.
Food and Drug Administration. (2020, April 5). Generic drug development. U.S. Food & Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drug-development.
11.
FuchsV. R. (1986). Physician-induced demand: A parable. Journal of Health Economics, 5(4), 367–380.
12.
GadreA.SardeshpandeN. (2017). Cut practice in private healthcare. Economic & Political Weekly, 52(48), 12–14.
13.
Government of India (GoI). (2004, November). Interim report of the Committee to Examine the Span of Price Control (including Trade Margin) for Medicines. Department of Chemicals and Petrochemicals.
14.
GoI. (2005, September). Report of the task force to explore options other than price control for achieving the objective of making available life-saving drugs at reasonable prices. Department of Chemicals and Petrochemicals.
15.
GoI. (2016). Report of the Committee on High Trade Margins in the Sale of Drugs. Department of Pharmaceuticals.
16.
GoI. (2017). National health accounts estimates for India: 2014–15. National Health Accounts Technical Secretariat, National Health Systems Resource Centre, Ministry of Health and Family Welfare.
17.
GoI. (2019, February). Pricing of drugs with special reference to DPCO 2013. 54th Standing Committee on Chemicals and Fertilisers, Department of Chemicals and Fertilisers.
18.
GuptaY. K.RamachandranS. S. (2016). Fixed dose combinations: Issues and challenges in India. Indian Journal of Pharmacology, 48(4), 347–349.
19.
India Brand Equity Foundation (IBEF). (2017). Sector report: Pharmaceutical(Monthly report). Indian Brand Equity Foundation. https://www.ibef.org/industry/pharmaceutical-india.aspx
20.
India Brand Equity Foundation (IBEF). (2018). Sector report: Pharmaceutical(Monthly report). Indian Brand Equity Foundation. https://www.ibef.org/industry/pharmaceutical-india.aspx
21.
India Brand Equity Foundation (IBEF). (2019). Sector report: Pharmaceutical(Monthly report). Indian Brand Equity Foundation. https://www.ibef.org/industry/pharmaceutical-india.aspx
22.
Indian Council of Medical Research, Public Health Foundation of India, & Institute of Health Metrics and Evaluation. (2017, November). India: Health of the nation’s states: Disease burden trends in states of India (1990 to 2016). http://www.healthdata.org/sites/default/files/files/policy_report/2017/India_Health_of_the_Nation’s_States_Report_2017.pdf
23.
International Federation of Pharmaceutical Manufacturers and Associations. (2017, February). The pharmaceutical industry and global health: Facts and figures 2017.
24.
JohnsonE. M. (2014). Physician-induced demand. In CulyerA. J. (Ed.), The encyclopedia of health economics (Vol. 3, pp. 77–82). Elsevier. https://doi.org/10.1016/B978-0-12-375678-7.00805-1
25.
JosephR. K. (2011). The R&D scenario in Indian pharmaceutical industry(RIS Discussion Paper No. 176). Research and Information Systems for Developing Countries.
26.
JosephR. K. (2016). Pharmaceutical industry and public policy in post-reform India. Routledge.
27.
KastorA.MohantyS. K. (2018). Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in India: Do Indian households face distress health financing? PLoSONE, 13(5), e0196106. https://doi.org/10.1371/journal.pone.0196106
28.
KhanA. N.KharR. K. (2015). Current scenario of spurious and substandard medicines in India: A systematic review. Indian Journal Pharmaceutical Science, 77(1), 2–7.
29.
KremerM. (2002). Pharmaceuticals and the developing world. Journal of Economic Perspectives, 16(4), 67–90.
30.
KrishnaA. (2010). One illness away: Why people become poor and how they escape poverty?Oxford University Press.
31.
LakdawallaD. N. (2018). Economics of pharmaceuticals industry. Journal of Economic Literature, 56(2), 297–449.
32.
LakdawallaD. N.GoldmanD. P.MichaudP. C.SoodN.LempertR.CongZ.de.Vries H.GutierrezI. (2009). U.S. pharmaceutical policy in a global marketplace. Health Affairs, 28(1), 138–150.
33.
LalithaN. (2002). Indian pharmaceutical industry in WTO regime: A SWOT analysis. Economic & Political Weekly, 37(34), 3542–3555.
34.
LalithaN. (2008). Tamil Nadu government intervention and prices of medicines. Economic & Political Weekly, 43(1), 66–71.
35.
MazumdarM. (2013). Performance of pharmaceutical companies in India: A critical analysis of industrial structure, firm specific resources, and emerging strategies. Springer-Verlag.
36.
MehtaA.FarooquiH. H.SelvarajS. (2016). A critical analysis of concentration and competition in the Indian pharmaceutical market. PLoS ONE, 11(2), e0148951.
37.
MondalS. S.PingaliV. (2015). Competition law and the pharmaceutical sector in India(Working Paper No. 2015–11–02). Indian Institute of Management.
38.
MudurG. S. (2017 December 17). Profiteer slur on hospital. The Telegraph. https://www.telegraphindia.com/india/profiteer-slur-on-hospital/cid/1329503
39.
MulinariS. (2016). Regulating pharmaceutical industry marketing: Development, enforcement and outcome of marketing rules. Sociology Compass, 10(1), 74–86.
40.
NairA. (1965). Drug prices: Is there a case for enquiry? Economic & Political Weekly, 17(14), 593.
41.
National Institute of Biologicals. (2016). Survey of extent of problems of spurious and not of standard quality drugs in the country—2014–2016. Ministry of Health and Family Welfare, Government of India. http://www.indiaenvironmentportal.org.in/files/file/National%20Drug%20Survey%202014-16.pdf
42.
National Pharmaceutical Pricing Authority. (2018). Office memorandum: File no. 27(2)/2017-Div-III/NPPA dated 20/2/2018. Department of Pharmaceuticals, Government of India. http://www.nppaindia.nic.in/order/overcharging_details(20022018).pdf
43.
Organisation of Pharmaceutical Producers of India (OPPI). (2000–2017). Annual reports, 2000–2017. https://www.indiaoppi.com
44.
Public Health Foundation of India. (2012). Rapid assessment and potential scale up of the Jan Aushadhi Pariyojana. Author.
45.
RaghavanP.RajagopalD. (2018, September 13). Government prohibits 328 fixed dose combinations. Economic Times. https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/government-prohibits-328-fixed-dose-combinations/articleshow/65787565.cms
46.
RAND. (2008). Regulating drug prices: US policy alternatives in the global context. RAND Research Highlights. RAND Health, RAND Corporation.
47.
RaneW. (1996). Analysis of drug prices, 1980 to 1995. Economic & Political Weekly, 31(34), 2331–2339.
48.
RaneW. (2002). Marginal rise in cardiovascular products: Prices of prescription drugs. Economic & Political Weekly, 37(33), 3402–3404.
49.
RNCOS. (2015, September). Indian generic drug market outlook 2020. Author.
50.
SelvarajS. (2007, July 30). How effective is India’s drug price control regime? Harvard School of Public Health. https://cdn1.sph.harvard.edu/wp-content/uploads/sites/114/2012/10/RP256.pdf
51.
SelvarajS.FarooquiH. H.KaranA. (2018) Quantifying the financial burden of households’ out-of-pocket payments on medicines in India: A repeated cross-sectional analysis of National Sample Survey data, 1994–2014. British Medical Journal Open, 8(5), e018020. https://doi.org/10.1136/bmjopen-2017-018020.
52.
SenS. (2018, April 9). Govt wants to use blockchain to bust fake drugs in India. Factor Daily. https://factordaily.com/niti-aayog-blockchain-for-drugs-in-india/
53.
Singh & Associates. (2018, February 20). Indian pharmaceutical companies: Abbreviated new drug application approvals 2017. Mondaq. https://www.mondaq.com/india/Food-Drugs-Healthcare-Life-Sciences/674750/Indian-Pharmaceutical-Companies-Abbreviated-New-Drug-Application-Approvals-2017
54.
SinghP.RaviS.DamD. (2020). Medicines in India: Accessibility, affordability and quality(Brookings India Research Paper No. 032020–01). Brookings Institution India Center. https://www.brookings.edu/wp-content/uploads/2020/03/Medicines-in-India_for-web-1-1.pdf
55.
SoodN.VriesH. de.GutierrezI.LakdawallaD. N.GoldmanD. P. (2009). The effect of regulation on pharmaceutical revenues: Experience in nineteen countries. Health Affairs, 28(1), 125–137.
56.
SrinivasI. (2014). The myth of branded generics. Economic & Political Weekly, 49(38), 12–15.
57.
SrinivasanS. (2001). Drug price control. Economic & Political Weekly, 36(12), 997–998.
58.
SrinivasanS. (2018). FDC ban and endless rounds of litigation. Economic & Political Weekly, 53(51), 16–18.
59.
SrinivasanS.ShivaM.AisolaM. (2016). Cleaning up the pharmacy industry: A landmark ban on irrational drugs. Economic & Political Weekly, 51(14), 21–23.
‘t HoenE. (2002). TRIPS, pharmaceutical patents, and access to essential medicines: A long way from Seattle to Doha. Chicago Journal of International Law, 3(1), 27–46.
62.
World Health Organization. (2017). A study on the public health and socioeconomic impact of substandard and falsified medical products. https://www.who.int/medicines/regulation/ssffc/publications/SE_Study_EN.pdf.
